Aktis Oncology
NASDAQ: AKTSBoston, US · Founded 2020 · Delaware corporation · 102 employees on LinkedIn · 12 known investors
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.
Founders & leadership
Aktis Oncology was founded in 2020 by Todd Foley and Patrick Baeuerle.
TF
PB
SR
Shulamit Ron-BiggerExecutive
Board
HS
ON
AL
MR
KH
Ken HerrmannBoard director
LS
Lloyd SegalBoard director
Investors · 12
Andreessen HorowitzMenlo Park · $500K – $50M
EcoR1 CapitalSan Franciscovia Oleg Nodelman · board
MPM BioImpactBoston · $1M – $15M
MRL Ventures FundCambridge · $25M
RA CapitalBoston
TCG CrossoverPalo Alto
Vida VenturesLos Angelesvia Helen S. Kim · board
Janus Henderson InvestorsreportedLondon
RTW Investments L.P.reportedNew York
Also in the syndicate · 3
Bristol Myers SquibbEli LillyMerck & Co.
Reported raises · per SEC filings
Form D private placements$175M disclosed across 1 of 2 rounds · 2024–2026
▶$175MraisedOct 2024 · 39 investors · BiotechnologyRule 506(b)
▶$175MraisedOct 2024 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Helen S. KimDirector
- Shulamit Ron-BiggerExecutive Officer
- Ken HerrmannDirector
- Lloyd SegalDirector
- Oleg NodelmanDirector
- Andrew LevinDirector
- Matthew RodenExecutive Officer, Director
- Todd FoleyDirector
- Offering amount
- $175M
- Amount sold
- $175M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapBioworld25 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Kite Pharma17 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Solu16 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Aktis Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Aktis Oncology do?
- Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.
- Who founded Aktis Oncology?
- Aktis Oncology was founded by Todd Foley, Patrick Baeuerle in 2020.
- Who are Aktis Oncology's investors?
- Aktis Oncology's investors include Andreessen Horowitz, EcoR1 Capital, MPM BioImpact, MRL Ventures Fund, RA Capital, TCG Crossover, Vida Ventures, Janus Henderson Investors and 1 more.
- How much funding has Aktis Oncology raised?
- Aktis Oncology has disclosed $175M raised across 1 of its 2 known rounds.
- Where is Aktis Oncology headquartered?
- Aktis Oncology is headquartered in Boston, US.